Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00087698 · OUTCOME

The 1 and 2 Year Disease-Free Survival Rate (Percentage)

Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma · Source last updated 2009-05-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
1 year and 2 years

What was measured

Kaplan-Meier estimates of the percentage of participants still alive at 1-year and 2-years, based upon the total number of participants who had surgery.

Analysis population: All participants who had undergone surgery.

Groups in this outcome

Pemetrexed

pemetrexed: 500 mg/m2, intravenous, every 21 days x 4 cycles cisplatin: 75 mg/m2, intravenous, every 21 days x 4 cycles chemotherapy, surgery then chest radiation x 54 gray (Gy)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pemetrexed57

Reported measurements

1-Year Disease-Free Rate
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Pemetrexed61.40Not reported47.5372.63Not reported
2-Year Disease-Free Rate
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Pemetrexed33.24Not reported21.4545.47Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        47.53
        upper Limit
        72.63
        value
        61.40
    title
    1-Year Disease-Free Rate
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        21.45
        upper Limit
        45.47
        value
        33.24
    title
    2-Year Disease-Free Rate
denoms
  1. counts
    1. group Id
      OG000
      value
      57
    units
    Participants
description
Kaplan-Meier estimates of the percentage of participants still alive at 1-year and 2-years, based upon the total number of participants who had surgery.
dispersion Type
95% Confidence Interval
groups
  1. description
    pemetrexed: 500 mg/m2, intravenous, every 21 days x 4 cycles cisplatin: 75 mg/m2, intravenous, every 21 days x 4 cycles chemotherapy, surgery then chest radiation x 54 gray (Gy)
    id
    OG000
    title
    Pemetrexed
param Type
MEAN
population Description
All participants who had undergone surgery.
reporting Status
POSTED
time Frame
1 year and 2 years
title
The 1 and 2 Year Disease-Free Survival Rate (Percentage)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice